The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changes in FDG PET SUV and correlation with Ki-67 following 2 weeks of aromatase inhibitor therapy or trastuzumab in a pilot imaging study.
H. M. Linden
No relevant relationships to disclose
B. F. Kurland
No relevant relationships to disclose
R. B. Livingston
No relevant relationships to disclose
G. K. Ellis
No relevant relationships to disclose
V. K. Gadi
No relevant relationships to disclose
J. M. Specht
No relevant relationships to disclose
J. Gralow
Research Funding - Amgen; Genentech; Novartis; Roche
L. Peterson
No relevant relationships to disclose
E. K. Schubert
No relevant relationships to disclose
S. Xiaoyu
No relevant relationships to disclose
D. A. Mankoff
No relevant relationships to disclose